Literature DB >> 29594352

Analysis of membranous Ki-67 staining in breast cancer and surrounding breast epithelium.

Gábor Cserni1,2.   

Abstract

Membranous Ki-67 staining with the MIB-1 antibody has been described in hyalinising trabecular adenomas of the thyroid and sclerosing haemangiomas of the lung. Its relatively rare occurrence in breast tumours has also been documented. The aim of the present study was to assess the rate of any membranous MIB-1 staining in breast specimens. The staining was performed at room temperature with 1:100 dilution of the antibody. One hundred four core needle biopsies and 41 operative specimens were analysed. Membranous staining was noted in 36/144 invasive carcinomas, 20/42 in situ carcinomas and 46/99 cases of peritumoural benign/normal breast epithelium. Most often, it presented as focal and partial polarised luminal membranous staining although complete circumferential staining also occurred, and membranous labelling was sometimes accompanied by cytoplasmic staining, too. In a few cases tested, greater dilution of the primary antibody did not abolish the membranous staining, which was absent with the SP6 monoclonal Ki-67 antibody. The membranous staining of invasive tumours showed no association with histological grade, lumen formation, oestrogen or progesterone receptor status or the Ki-67 nuclear labelling. In contrast, it was associated with a HER2-positive status, although it occurred in all molecular subtypes approached by immunohistochemistry. The background of this membranous staining remains elusive. It is unlikely to represent an artefact. At least partial sharing of an epitope of the nuclear Ki-67 protein with an unidentified membranous protein and some functional differences between membranous staining producing tumours and tumours lacking this pattern of staining may both contribute to some extent.

Entities:  

Keywords:  Breast cancer; HER2; Immunohistochemistry; Ki-67; MIB-1; Membranous staining

Mesh:

Substances:

Year:  2018        PMID: 29594352     DOI: 10.1007/s00428-018-2343-z

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  25 in total

1.  Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67.

Authors:  J Gerdes; L Li; C Schlueter; M Duchrow; C Wohlenberg; C Gerlach; I Stahmer; S Kloth; E Brandt; H D Flad
Journal:  Am J Pathol       Date:  1991-04       Impact factor: 4.307

2.  Ki-67 Membranous Staining: Biologically Relevant or an Artifact of Multiplexed Immunofluorescent Staining.

Authors:  Dan Wang; Zhengyu Pang; Gina M Clarke; Sharon Nofech-Mozes; Kela Liu; Alison M Y Cheung; Robert J Filkins; Martin J Yaffe
Journal:  Appl Immunohistochem Mol Morphol       Date:  2016-07

3.  Reversed polarity of the glandular epithelial cells in micropapillary carcinoma of the large intestine and the EMA/MUC1 immunostain.

Authors:  Gábor Cserni
Journal:  Pathology       Date:  2014-10       Impact factor: 5.306

Review 4.  Ki67 in breast cancer: prognostic and predictive potential.

Authors:  Rinat Yerushalmi; Ryan Woods; Peter M Ravdin; Malcolm M Hayes; Karen A Gelmon
Journal:  Lancet Oncol       Date:  2010-02       Impact factor: 41.316

5.  Sclerosing haemangioma of the lung is positive for MIB-1 in cell membrane and cytoplasmic staining pattern.

Authors:  H Hattori
Journal:  Histopathology       Date:  2002-03       Impact factor: 5.087

Review 6.  [Pathological diagnosis, work-up and reporting of breast cancer. Recommendations of the 3rd Hungarian Consensus Conference on Breast Cancer].

Authors:  Gábor Cserni; Janina Kulka; Monika Francz; Balázs Járay; Endre Kálmán; Ilona Kovács; Tibor Krenács; Nóra Udvarhelyi; László Vass
Journal:  Magy Onkol       Date:  2016-06-20

7.  Cell membrane reactivity of MIB-1 antibody to Ki67 in human tumors: fact or artifact?

Authors:  Eugenio Leonardo; Marco Volante; Mattia Barbareschi; Alberto Cavazza; Angelo Paolo Dei Tos; Gianni Bussolati; Mauro Papotti
Journal:  Appl Immunohistochem Mol Morphol       Date:  2007-06

8.  How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists.

Authors:  Zsuzsanna Varga; Joachim Diebold; Corina Dommann-Scherrer; Harald Frick; Daniela Kaup; Aurelia Noske; Ellen Obermann; Christian Ohlschlegel; Barbara Padberg; Christiane Rakozy; Sara Sancho Oliver; Sylviane Schobinger-Clement; Heide Schreiber-Facklam; Gad Singer; Coya Tapia; Urs Wagner; Mauro G Mastropasqua; Giuseppe Viale; Hans-Anton Lehr
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

9.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.

Authors:  A Goldhirsch; J N Ingle; R D Gelber; A S Coates; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2009-06-17       Impact factor: 32.976

10.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.

Authors:  A Goldhirsch; E P Winer; A S Coates; R D Gelber; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2013-08-04       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.